

**CLAIMS**

1. Medicament to counteract the loss of cellular differentiation in tumour and non tumour pathologies characterised in that it comprises as active principle an effective amount of at least one inhibitor compound of Reverse Transcriptase (RT) said compound being able to bind the hydrophobic pocket on the RT subunit p66.  
5
2. Medicament according to claim 1 wherein the tumour pathologies are selected in the group of leukaemia and solid tumours such as epithelial tumors, mesenchymal tumors, tumors of the nervous system, teratocarcinomas, fibro- and osteo-sarcomas, colon carcinoma, breast carcinoma, glioma and hepatoma.  
10
3. The use of at least one inhibitor compound of Reverse Transcriptase for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies.
- 15 4. The use according to claim 3 wherein the compound reconverts the differentiated cells into phenotypically normal cells.
5. The use according to claim 3 wherein the tumour pathologies are selected in the group of leukaemia and solid tumours such as epithelial tumors, mesenchymal tumors, tumors of the nervous system, teratocarcinomas, fibro- and osteo-sarcomas, colon carcinoma, breast carcinoma, glioma and hepatoma.  
20
6. The use according to claims 3-5 wherein the compound is selected from the 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine class of compounds.
7. The use according to claims 3-5 wherein the compound is selected in the group of: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.  
25
8. The use according to claims 3-7 wherein the pharmaceutical compositions further comprise carriers and/or diluents and/or solvents and/or excipients for the preparation of compositions for oral, intravenous, intramuscular or hypodermic injection administration.  
30
9. The use according to claims 3-8 wherein the pharmaceutical compositions are in the form of pills, suspensions or solutions.

10. The use of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines for the preparation of pharmaceutical compositions with antiproliferative activity.

11. The use of at least one compound selected in the group of: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable  
5 derivatives thereof, for the preparation of pharmaceutical compositions with antiproliferative activity.